Showing 1121-1130 of 20391 results for "".
Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
https://reachmd.com/programs/cme/test-your-skills-and-learn-from-experts-on-il-13-inhibitors-in-moderate-to-severe-atopic-dermatitis/37624/Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
https://reachmd.com/programs/cme/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/54306/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Revolutionizing Aesthetic Medicine and Dermatology with Artificial Intelligence
https://reachmd.com/ma-issues-index/2025-mar-apr/revolutionizing-aesthetic-medicine-and-dermatology-with-artificial-intelligence/36064/This article explores the possibilities of AI and how it can be ethically utilized to enhance aesthetic medicine and marketing to grow one’s practice to its maximum potential.IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
https://reachmd.com/programs/cme/ibd-masterclass-foundations-of-pathophysiology-and-targeted-therapy/49149/Examine the biological mechanisms underlying IBD, including genetic, microbial, environmental, and immune pathways that inform therapeutic targets.Chairperson’s Perspective: Incorporating Novel Treatment Options for Schizophrenia Into Clinical Practice - Overcoming Clinical Inertia
https://reachmd.com/programs/cme/chairpersons-perspective-incorporating-novel-treatment-options-for-schizophrenia-into-clinical-practice-overcoming-clinical-inertia/54751/Learn expert insights on muscarinic antipsychotics in schizophrenia, with practical guidance on patient selection, titration, and managing adverse effects.TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
https://reachmd.com/programs/cme/ttr-levels-and-associated-disease-risk-insights-from-2025-pns-conference/36192/Review recent data from the UK Biobank showing the increased risk of vascular and cognitive comorbidities associated with naturally low transthyretin levels.Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
https://reachmd.com/programs/cme/chairpersons-perspective-evidence-informed-clinical-decision-making-in-her2-overexpressed-and-trop2-targeted-nsclc/39894/Study HER2 IHC testing, efficacy, and NCCN guidance supporting ADC sequencing for HER2-overexpressed NSCLC and TROP2-directed ADCs for EGFR-TKI–resistant NSCLC.Inside the Cataracts Studio: Advanced Fluidics, Ergonomics, and Techniques for Complex Cases - Introducing Robotic SLACS
https://reachmd.com/programs/cme/inside-the-cataracts-studio-advanced-fluidics-ergonomics-and-techniques-for-complex-cases-introducing-robotic-slacs/33177/Explore SLACS for cataract surgery, which features a robotic femtosecond laser integrated into the operating suite that can be utilized for complex cases.Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
https://reachmd.com/programs/cme/tbd/37674/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
https://reachmd.com/programs/cme/real-world-igan-a-case-based-approach-to-maximizing-kidney-preservation/26635/Are you implementing the new KDIGO guidelines for IgA nephropathy? Learn how to apply them in clinical practice using a real-world patient case.